Contraindicated in patients with severe hepatic impairment.
- TRADE NAMES: Agrylin (Shire); Xagrid (Shire)
- INDICATIONS: Essential thrombocytopenia; to reduce elevated platelet count and the risk of thrombosis
- CLASS: Phospholipase A2 inhibitor
- HALF-LIFE: 1.3 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aminophylline, Aspirin, Cilostazol, Enoximone, Fluvoxamine, Fondaparinux, Inamrinone, Milrinone, Olprinone, Sucralfate
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
